Ezetimibe
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
- Ezetimibe
- Pharmacist Assessment Report
- Ezetimibe: From Hyperlipidaemia to Cholesterol-Ester Transfer Protein Deficiency
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Australia Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Ezetimibe: From Hyperlipidaemia to Cholesterol-Ester Transfer Protein Deficiency
One-Sentence Summary
Ezetimibe is a cholesterol absorption inhibitor. Predictions and scores on this page come from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. The TxGNN model predicts it may be relevant to cholesterol-ester transfer protein (CETP) deficiency, but there are 0 clinical trials and 2 publications (neither studying ezetimibe in this condition), so this remains a computational prediction only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hyperlipidaemia, familial hyperlipidaemia, homozygous familial hypercholesterolaemia and sitosterolemia (relations recorded in the knowledge graph; the Australian licence records compiled for this report contain no approved indication text) |
| Predicted New Indication | Cholesterol-ester transfer protein deficiency |
| TxGNN Prediction Score | 0.9909 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (2 of 2 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 2 (valid: 2) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on general knowledge, ezetimibe inhibits NPC1L1-mediated intestinal cholesterol absorption and lowers LDL cholesterol.
CETP deficiency is characterised by raised HDL cholesterol and reduced LDL cholesterol. On this basis there is no clear therapeutic reason to add an LDL-lowering agent. The high score (0.9909) comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. The prediction should be treated as a hypothesis only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 40911366 | 2025 | Review | European Heart Journal | General review of lipid-lowering targets (LDL-C, triglycerides, apoB, Lp(a)); does not examine ezetimibe in CETP deficiency |
| 31779098 | 2019 | Animal model study | International Journal of Molecular Sciences | Heterozygous Ldlr-deficient hamster model used to test PCSK9 antibody in hyperlipidaemia and atherosclerosis; not about ezetimibe or CETP deficiency |
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 13440J | Zient 10mg | Tablet 10 mg | Not available in the compiled data |
| ARTG 10201X | Rosuzet Composite Pack | Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 20 mg (as calcium) | Not available in the compiled data |
Note: Rosuzet is a combination pack (ezetimibe with rosuvastatin), so its licence does not describe the approval of ezetimibe as a single ingredient.
Safety Considerations
- Relations recorded in the knowledge graph (not label text): contraindication links to pancreatitis, liver disease, gallbladder disease, myopathy, muscular disease, skeletal muscle disease, familial periodic paralysis, substance abuse/dependence, rhabdomyolysis and nodular fasciitis.
- Drug Interactions: 100 interactions were found. Moderate-level interactions include chenodeoxycholic acid, eluxadoline, rosuvastatin and simvastatin. Several others (e.g. calcitriol, pantoprazole, glimepiride, metformin, omeprazole, morphine) are of unknown severity.
Please refer to the TGA-approved Product Information (PI) for authoritative warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a model score. No clinical trials exist, and neither retrieved publication studies ezetimibe in CETP deficiency. The condition already features low LDL-C, so a therapeutic rationale is lacking.
To proceed, the following is needed:
- Mechanistic evidence for ezetimibe in CETP deficiency, and a clear unmet clinical need
- Mechanism of action data (MOA)
- TGA Product Information warnings and contraindications for safety screening
- Direct clinical or observational studies of ezetimibe in this condition
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.